关于这个播客 🔗

更新频率:
every 21 days
平均音频长度:
53 minutes
嘉宾访谈
视频播客
英语
美国
11 集
自从 2025年8月1日
episodic

最新一集 🔗

Lindsay Edwards went from producing UK top ten singles with Sting and Whitney Houston to pioneering the first data science group at GSK — and he's carried the same creative instinct into machine learning ever since. Now CTO of Relation Therapeutics, he's one of the clearest-eyed voices in the ind...

搜索以前的节目

搜索Transcribed以前的节目。

以前的节目

Jacob Berlin spent years perfecting a microarray chip the size of a fingernail before he thought about starting a company. Now, as cofounder and CEO of Terray Therapeutics, he's using that hardware to generate chemistry data at a scale the industry has never seen, and arguing that models without ...
Kate Haviland knows how to push through clinical setbacks and turn breakthrough science into life-changing therapies. As former CEO of Blueprint Medicines, she led the team that took Ayvakit from a failed Phase 3 to a $500M blockbuster — by cutting the dose by 87% and betting on a patient populat...
Janice Chen cofounded Mammoth Biosciences straight out of Jennifer Doudna's lab — and she's been rewriting the CRISPR playbook ever since. In this episode, she tells host and Benchling CEO Sajith Wickramasekara about what it really takes to build a platform company, why the biggest barriers to ...
Nicole Paulk talks about turning moonshots into companies, why unpopular ideas are the right ones to pursue, and how biotech has to move faster and cheaper to survive.
Gleb Kuznetsov talks about about ditching Google for grad school, what it takes to build a true platform company, and where AI-driven drug discovery is headed.
Andrew Bellinger discusses what it takes to build new drug modalities from scratch, the bold bets and tough calls that shaped Verve’s journey, and lessons in building new companies from first-in-class science. * Editor's note: The interview was recorded following the announcement of Verve's acqui...
Jake Becraft reflects on making bold bets in mRNA, the journey from lab bench to biotech founder, and the state of science today. (00:00) Introduction to Jake Becraft (00:39) Betting big on mRNA — before it was a proven modality (11:34) Getting your drugs to patients (25:47) The state of modern b...
Karen Akinsanya unpacks the rise of computational drug discovery, what it takes to prove impact of new technologies, and the importance of setting realistic expectations for AI. (00:00) Introduction to Karen Akinsanya (01:54) Pursuing big technological shifts (06:24) How computation is setting th...
Sara Kenkare-Mitra talks about resilience, risk, and the kind of leadership it takes to save failing drug programs — and make medicines that matter. (00:00) Introduction to Sara Kenkare-Mitra (00:36) Turning a (nearly) failed program into a bestselling drug (08:33) Learning from industry legends ...
免责声明: 本页面嵌入的播客和封面图片来自 Benchling,归其所有者所有,与 Listen Notes, Inc. 无关联,也未获得 Listen Notes, Inc. 背书。